Current prospects of fluoroquinolones: pazufloxacin. A review
Fluoroquinolones (FQ) are one of the most valuable groups of antibacterial drugs in clinical practice. Ciprofloxacin and levofloxacin are drugs with the largest contribution to the structure of FQ consumption both in the Russian Federation and in the world. The widespread use of FQ in recent years h...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
"Consilium Medicum" Publishing house
2025-01-01
|
| Series: | Терапевтический архив |
| Subjects: | |
| Online Access: | https://ter-arkhiv.ru/0040-3660/article/viewFile/680092/202486 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849338210543468544 |
|---|---|
| author | Olga I. Butranova Sergey K. Zyryanov Anna R. Melnikova Anastasia E. Matsepuro |
| author_facet | Olga I. Butranova Sergey K. Zyryanov Anna R. Melnikova Anastasia E. Matsepuro |
| author_sort | Olga I. Butranova |
| collection | DOAJ |
| description | Fluoroquinolones (FQ) are one of the most valuable groups of antibacterial drugs in clinical practice. Ciprofloxacin and levofloxacin are drugs with the largest contribution to the structure of FQ consumption both in the Russian Federation and in the world. The widespread use of FQ in recent years has been accompanied by an intensive growth of antibiotic resistance of the main pathogens, including those from the ESKAPE group, which limits the possibilities of effective antibiotic therapy for a wide range of infectious diseases. In this situation, we have an attractive possibility of including a new FQ for the Russian pharmaceutical market, pazufloxacin, in the treatment regimens for patients with infectious diseases. This is a third-generation FQ, whose spectrum of antibacterial action, as has been demonstrated in the published studies, is close to that of the beta-lactam ABP ceftazidime. The studies considered in our narrative review indicate a high level of clinical efficacy and safety of this FQ, which suggests broad prospects for its use in the treatment of infectious diseases taking in account accelerated antibiotic resistance. |
| format | Article |
| id | doaj-art-8a0423f6aa3e412d879c573e769b7509 |
| institution | Kabale University |
| issn | 0040-3660 2309-5342 |
| language | Russian |
| publishDate | 2025-01-01 |
| publisher | "Consilium Medicum" Publishing house |
| record_format | Article |
| series | Терапевтический архив |
| spelling | doaj-art-8a0423f6aa3e412d879c573e769b75092025-08-20T03:44:28Zrus"Consilium Medicum" Publishing houseТерапевтический архив0040-36602309-53422025-01-0197650952110.26442/00403660.2025.06.20326878695Current prospects of fluoroquinolones: pazufloxacin. A reviewOlga I. Butranova0https://orcid.org/0000-0001-7729-2169Sergey K. Zyryanov1https://orcid.org/0000-0002-6348-6867Anna R. Melnikova2https://orcid.org/0009-0002-1474-5014Anastasia E. Matsepuro3https://orcid.org/0009-0000-1961-609XPeoples' Friendship University of Russia named after Patrice LumumbaPeoples' Friendship University of Russia named after Patrice LumumbaPeoples' Friendship University of Russia named after Patrice LumumbaPeoples' Friendship University of Russia named after Patrice LumumbaFluoroquinolones (FQ) are one of the most valuable groups of antibacterial drugs in clinical practice. Ciprofloxacin and levofloxacin are drugs with the largest contribution to the structure of FQ consumption both in the Russian Federation and in the world. The widespread use of FQ in recent years has been accompanied by an intensive growth of antibiotic resistance of the main pathogens, including those from the ESKAPE group, which limits the possibilities of effective antibiotic therapy for a wide range of infectious diseases. In this situation, we have an attractive possibility of including a new FQ for the Russian pharmaceutical market, pazufloxacin, in the treatment regimens for patients with infectious diseases. This is a third-generation FQ, whose spectrum of antibacterial action, as has been demonstrated in the published studies, is close to that of the beta-lactam ABP ceftazidime. The studies considered in our narrative review indicate a high level of clinical efficacy and safety of this FQ, which suggests broad prospects for its use in the treatment of infectious diseases taking in account accelerated antibiotic resistance.https://ter-arkhiv.ru/0040-3660/article/viewFile/680092/202486fluoroquinolonespazufloxacinantibiotic resistanceinfectious diseases |
| spellingShingle | Olga I. Butranova Sergey K. Zyryanov Anna R. Melnikova Anastasia E. Matsepuro Current prospects of fluoroquinolones: pazufloxacin. A review Терапевтический архив fluoroquinolones pazufloxacin antibiotic resistance infectious diseases |
| title | Current prospects of fluoroquinolones: pazufloxacin. A review |
| title_full | Current prospects of fluoroquinolones: pazufloxacin. A review |
| title_fullStr | Current prospects of fluoroquinolones: pazufloxacin. A review |
| title_full_unstemmed | Current prospects of fluoroquinolones: pazufloxacin. A review |
| title_short | Current prospects of fluoroquinolones: pazufloxacin. A review |
| title_sort | current prospects of fluoroquinolones pazufloxacin a review |
| topic | fluoroquinolones pazufloxacin antibiotic resistance infectious diseases |
| url | https://ter-arkhiv.ru/0040-3660/article/viewFile/680092/202486 |
| work_keys_str_mv | AT olgaibutranova currentprospectsoffluoroquinolonespazufloxacinareview AT sergeykzyryanov currentprospectsoffluoroquinolonespazufloxacinareview AT annarmelnikova currentprospectsoffluoroquinolonespazufloxacinareview AT anastasiaematsepuro currentprospectsoffluoroquinolonespazufloxacinareview |